Residual contamination in antineoplastic drug packaging.

Autor:	E Silva LS; Post Graduate Program in Health Sciences: Gynecology and Obstetrics, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil., Machado CDSB; Post Graduate Program in Health Sciences: Gynecology and Obstetrics, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil., Linden R; Analytical Toxicology Laboratory, Feevale University, Novo Hamburgo, RS, Brazil., Antunes MV; Analytical Toxicology Laboratory, Feevale University, Novo Hamburgo, RS, Brazil., da Silva LC; Analytical Toxicology Laboratory, Feevale University, Novo Hamburgo, RS, Brazil.; Graduate Program in Toxicology and Toxicological Analysis, Feevale University, Novo Hamburgo, RS, Brazil., Wayhs CAY; Center for Intravenous Drug Preparation, Department of Pharmacy, Hospital de Clínicas Porto Alegre, Porto Alegre, RS, Brazil., Capp E; Post Graduate Program in Health Sciences: Gynecology and Obstetrics, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.; Department of Gynecology and Obstetrics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil., Ness SLR; Center for Intravenous Drug Preparation, Department of Pharmacy, Hospital de Clínicas Porto Alegre, Porto Alegre, RS, Brazil.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Dec; Vol. 29 (8), pp. 1862-1867. Date of Electronic Publication: 2023 Jan 19.
DOI:	10.1177/10781552231151693
Abstrakt:	Introduction: The handling of antineoplastic drugs should follow strict supervision and safety rules to minimize the occupational exposure risks to professionals involved. The external surface contamination of drug vials is recognized as a health risk. So, our goal was to determine if there is residual contamination on the vials and containers surface of the antineoplastic drugs doxorubicin (DOX) and cyclophosphamide (CP). Methods: A cross-sectional study was conducted. Samples were collected using a uniform sampling procedure on the inner surfaces of the packages/boxes and the outer surfaces of the vials. The analyzes were executed by high-performance liquid chromatography/mass spectrometry (UHPLC-MS/MS). Results: A total of 209 samples were analyzed, 66 of CP and 143 of DOX. CP levels were detected in nine samples (13.63%), three were below the lower limit of quantification (LLQ) and the other six had contamination levels ranging from 1.24 to 28.04 ng/filter. DOX levels were detected in 36 samples (25.17%), two were below the LLQ and the others had levels between 1.32 and 664.84 ng/filter. The majority of samples with residual contamination were in vials (80.0%), however, boxes also showed contamination. Conclusions: The results revealed the presence of residual contamination in the vials and packages of CP and DOX drugs. Although the residues found in each sample are small, special care should be taken in the handling and disposal of the antineoplastic drugs. The use of personal protective equipment is fundamental while handling the vials and packaging of cytotoxic drugs. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu